Study: Psorent improves, controls symptoms of plaque psoriasis
SAN FRANCISCO A nonprescription topical solution made with a new formulation of liquor carbonis distillate known as Psorent is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis, according to research findings presented at the American Academy of Dermatology’s 2009 Annual Meeting NeoStrata, which markets Psorent, announced Tuesday.
“We knew, based on the preliminary study results we presented at the summer AAD, that in the treatment phase of this study, twice-daily LCD outperformed calcipotriol cream for control of psoriasis symptoms,” stated Alexa Kimball, a CURTIS researcher who was also a study investigator and author. “But we were encouraged by the fact that the improvements also persisted longer after patients stopped their twice-daily treatments for six weeks.”
The team’s conclusions are based on data from 55 patients who received treatment for up to 12 weeks and 43 patients who returned for re-assessment 6 weeks after treatment stopped.
“Because no single treatment is right for everyone, dermatologists are always looking for new ways to improve outcomes for their psoriasis patients,” stated Mark Lebwohl, chairman of the Department of Dermatology at The Mount Sinai School of Medicine in New York. “The results of this trial suggest that LCD may be an appropriate treatment choice for psoriasis patients with mild or moderate disease.”
Prasco enters marketing, distribution agreement with GSK
MASON, Ohio Prasco Labs announced Wednesday it has entered into a marketing and distribution agreement with GlaxoSmithKline.
FLONASE Nasal Spray will be the first product to be marketed under this agreement. Prasco, as GSK’s agent and on GSK’s behalf, will solicit orders for, and distribute, Fluticasone Propionate Nasal Spray to all trade classes in the United States under a GSK/Prasco label.
Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.
“We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry,” said E. Thomas Arington, Prasco CEO. “We look forward to working with GSK to provide more choices for patients in the generics market.”
The Female Health Co. receives FDA approval for new female contraceptive
CHICAGO The Female Health Company announced Wednesday that its FC2 Female Condom received approval from the Food and Drug Administration.
The FC2 is a woman-initiated barrier method that helps to protect against sexually transmitted infections (STIs), HIV/AIDS and unintended pregnancy.
FHC’s lower-cost second generation female condom will now be available for purchase and distribution in the United States. FDA approval also will enable the United States Agency for International Development to procure FC2 for distribution to global HIV/AIDS programs.